ACA Marketplace GLP-1 Coverage by Carrier and State (2026)

Educational insurance policy reference. Not medical, legal, or individualized coverage advice.

Three things follow from the key finding above, and they are the reason this page exists.

The 8.7% figure is not an orphan statistic. It comes from the LEVERAGE | AXIACI Obesity Coverage Nexus, with funding support from the Robert Wood Johnson Foundation. The source defines a carrier as a state + carrier combination, not a unique insurance company.

The source’s own summary, body text, and state table disagree about how many positive carrier-state offerings require Class 3 obesity. The three public answers are 22, 24, and 21 out of 26. The public table supports 21, and the arithmetic is shown below.

And the source’s population columns use 2025 enrollment. CMS’s final 2026 open-enrollment report is now public. Across the same nine states, CMS reports 4,111,979 Marketplace plan selections — 14.8% below the baseline’s 4,824,571-person market-segment total — but the two columns may not measure the same universe, so they cannot be substituted for one another.

None of this makes the baseline useless or fabricated. It makes it a dated snapshot with one unresolved internal BMI discrepancy, a historical enrollment denominator, and a counting unit that has to be explained before the number is quoted.

What does ACA Marketplace GLP-1 coverage by carrier and state show in 2026?

The most complete public national baseline found obesity-indication coverage in 26 of 300 carrier-state offerings — 8.7% — across nine states. The source reviewed 2026 plan documents and medical-necessity policies, but its covered-lives estimates use 2025 enrollment and its carrier identities are not disclosed in the public table.

The baseline comes from the Obesity Coverage Nexus, a project developed by LEVERAGE and its AXIACI platform with funding support from the Robert Wood Johnson Foundation. The project says it reviewed policies for 300 offerings to determine coverage and access conditions for Wegovy, Zepbound, and Saxenda. The public release names Christine Ferguson as lead investigator.

One definition governs every number below. The source counts a carrier-state offering, not a company. A carrier operating in twelve states can count twelve times because its plans and coverage requirements can differ by state. So 300 is not 300 unique insurance companies, and 26 is not 26 unique insurance companies.

The nine states, as published

Source: State rows, counts, BMI rules, and population figures from LEVERAGE | AXIACI, “Marketplace Plans: GLP-1s in 2026 — Coverage Shrinks as Barriers to Access Expand”. Totals and access shares calculated by The RX Index from those published rows. Verified July 31, 2026.

The five numbers anyone can reproduce from the public table

• 26 ÷ 300 = 8.7% of carrier-state offerings.
• The nine state rows sum to 2,778,895 people with reported access. That reconciles to the source’s rounded statement that access fell to 2.8 million enrollees.
• California represents 85.6% of those reported access lives. The calculation is 2,380,000 ÷ 2,778,895.
• Only 398,895 reported access lives are outside California. That is the total across the other eight states.
• The nine published state rows contain 4,824,571 people in the source’s market-segment column, with 57.6% assigned to a positive carrier-state offering.

California’s concentration

Which carriers and states have current 2026 evidence?

The July 31, 2026 reconciliation produces four different kinds of answer. North Dakota has a confirmed state benefit floor. Delaware, New York, Pennsylvania, and West Virginia have current carrier-policy evidence without a complete plan-level join. Rhode Island and Vermont have current public evidence that conflicts with their positive baseline rows. California and Georgia remain unresolved at the current drug-and-contract level.

The statuses look fussy because “covered” is not one fact. A benefit must exist in the contract, the drug must be covered under the plan’s pharmacy terms, and the member must meet the applicable utilization-management criteria. A carrier medical policy can describe approval criteria without proving that a particular Marketplace contract contains the benefit.

Source: The RX Index reconciliation of Covered California’s 2026 plan data, North Dakota’s EHB materials, Highmark J-1388, Highmark J-1389, Excellus Pharmacy-03, HealthSource RI’s 2026 plan guide, Neighborhood policy 000826, BCBSRI’s GLP-1 quick reference, MVP’s current weight-loss coverage page, and Blue Cross VT’s 2026 medication resources. Verified July 31, 2026.

What changed between the baseline and July 31, 2026?

Two baseline-positive carrier-state offerings — one in Rhode Island and one in Vermont — are no longer supported by current public evidence. Across those two markets, the two active carrier families in each state publish current weight-loss or obesity-indication exclusions. That is movement in two positive baseline rows, not four.

A plan year is not a frozen object. Contracts are generally annual, while formularies and utilization-management policies can be revised during the year. The correct way to show that movement is to preserve the historical baseline and add a dated current-evidence field, not silently overwrite the old row.

Rhode Island

The baseline reports one positive Rhode Island carrier-state offering with a Class I threshold and 34,741 people with access.

HealthSource RI’s 2026 individual-market guide shows two carrier families: Blue Cross & Blue Shield of Rhode Island and Neighborhood Health Plan of Rhode Island. The guide also says its comparison is not the contract and directs members to the carrier’s Evidence of Coverage for actual benefits, limitations, and exclusions.

Neighborhood’s Benefit Exclusion policy 000826 has review dates of December 22, 2025 and June 2, 2026. Its Commercial benefit exclusions include medications used for weight loss, and the version history says the June 2 update added those medications to the Commercial line.

BCBSRI’s GLP-1 provider quick reference, updated in December 2025, says Wegovy, Zepbound, and Saxenda are excluded for weight loss on most BCBSRI plans and points to exceptions for certain employer groups. HealthSource RI plans are individual-market products, not employer-group coverage. The exact Marketplace EOC still controls, but current public evidence does not identify a positive Rhode Island carrier family for ordinary obesity-indication coverage.

Vermont

The baseline reports one positive Vermont carrier-state offering with a Class II threshold and 10,616 people with access.

MVP’s current coverage page says Vermont Commercial and Exchange plans do not cover GLP-1 medications for weight loss. It separately says other accepted indications may be covered depending on the plan.

Blue Cross VT’s October 2025 provider notice says GLP-1 medications FDA-approved for weight loss would no longer be covered beginning January 1, 2026. Its November 2025 provider notice separately addresses Wegovy coverage for prevention of major adverse cardiovascular events. Its current medication-resources page directs QHP members to the 2026 plan-specific resources. Separate coverage for another FDA-approved indication does not convert into obesity coverage.

That is the whole thesis of this page in one state: same molecule, same carrier family, different indication, different answer. A dataset that records “Wegovy: yes” or “Wegovy: no” without an indication column can be wrong in both directions.

Source: LEVERAGE | AXIACI baseline; HealthSource RI 2026 guide; Neighborhood policy 000826; BCBSRI GLP-1 quick reference; MVP coverage page; Blue Cross VT October 2025 provider notice and November 2025 provider notice. Verified July 31, 2026.

How many positive offerings restrict access to BMI 40 and above?

The public baseline gives three different answers: 22, 24, and 21 out of 26. The source’s key-findings bullet yields 22. Its body text yields 24. Counting its published state table yields 21, or 80.8%. The table-derived number is the only one a reader can reproduce from the public state rows, but the source’s nonpublic carrier detail could contain information the release does not show.

This matters because “almost every positive plan requires BMI 40” is one of the baseline’s most portable findings, and the exact public count is unsettled.

• The key-findings bullet says all but four positive carriers limit coverage to BMI 40 and above. That means 22 of 26.
• Later, the body says all but two plans limit access to that group. That means 24 of 26.
• Counting the public table: the sub-Class-III rows are Georgia’s one Class I offering, two New York offerings at Class II and Class I, Rhode Island’s one Class I offering, and Vermont’s one Class II offering. That is five below Class III, leaving 21 of 26 at Class III.

For adult BMI categories, the CDC defines Class 1 as 30 to less than 35, Class 2 as 35 to less than 40, and Class 3 or severe obesity as 40 or greater.

Source: The three counts are extracted or calculated from LEVERAGE | AXIACI’s public release. The table-derived row counts Georgia, New York Carriers 2 and 3, Rhode Island, and Vermont as below Class III. Verified July 31, 2026.

Two smaller internal problems sit beside it. The release says the share of Americans with the highest obesity class is “less than 10%” in one place and “less than 9%” in another. We do not choose between those statements here.

The release also says that if the same 24.5 million people reenrolled, less than 10% would have coverage. Its own public state rows sum to 2,778,895 reported access lives. Dividing 2,778,895 by 24.5 million gives 11.3%, not less than 10%.

The safe publication rule is simple: quote 26 of 300 and the nine-state table as the dated baseline; do not quote a single Class-III share without explaining the 22/24/21 discrepancy; and do not repeat the source’s “less than 10% of enrollees” sentence as though the public arithmetic supports it.

How do the baseline population figures compare with CMS’s 2026 enrollment report?

Across the nine baseline states, CMS reports 4,111,979 cumulative 2026 Marketplace plan selections. That is 712,592 — 14.8% — below the baseline’s 4,824,571-person market-segment total. The difference is real arithmetic, but it is not proof that either source is wrong because the two columns may cover different populations.

The baseline says its population figures are based on 2025 enrollment and would be adjusted after 2026 open enrollment. CMS published its 2026 national snapshot on January 28, 2026.

Source: Baseline column from LEVERAGE | AXIACI. CMS column from Marketplace 2026 Open Enrollment Period Report: National Snapshot, published January 28, 2026. Differences and percentages calculated by The RX Index. CMS data runs through January 15, 2026 for the federal platform and January 10, 2026 for state-based exchanges. Verified July 31, 2026.

Two cautions stop this table from becoming a fake correction. First, CMS counts Marketplace plan selections. The baseline labels its denominator “total number of people in the market segment,” which may include a broader individual-market universe. The source does not publish enough denominator documentation to prove that the columns are identical. Second, plan selections are not effectuated enrollment. CMS says consumers generally must pay the first month’s premium for coverage to take effect and that the report does not count effectuated enrollments.

For those reasons, the CMS numbers should not be substituted into the baseline’s access-life rows.

The New York footnote does check out at the rounded level

The baseline says most New York individual-market lives sit in the Essential Plan and gives a rounded figure of 1.7 million. CMS reports 1,727,055 people in New York’s Essential Plan Expansion as of January 10, 2026. That supports the scale of the baseline’s rounded footnote. It does not prove every other row, and it does not convert Essential Plan enrollment into QHP enrollment.

Why does California show 14 offerings when Covered California says 11 companies?

Both numbers can be true because they count different units. Covered California says 11 health insurance companies offer plans in 2026. The official product-price workbook contains 14 consumer-facing product lines that resolve to 11 unique HIOS issuer IDs. The public baseline’s count of 14 aligns with those product lines, but that alignment is an inference from the official roster, not proof of the baseline producer’s internal counting method.

A HIOS issuer ID is an issuer-level identifier used in federal Marketplace data. It is a useful join key for separating a consumer-facing product name from the legal issuer behind it.

Source: Product-line names and HIOS issuer IDs normalized by The RX Index from the official Covered California 2026 QHP Individual Product Prices workbook. Company count cross-checked against Covered California’s August 14, 2025 rates-and-plans announcement. Verified July 31, 2026.

Fourteen minus the three repeated issuer pairs — Anthem, Blue Shield, and Health Net — is 11. The practical rule is to publish both units: 14 product lines from 11 unique HIOS issuers. Calling both numbers “carriers” without defining the unit creates a disagreement that does not need to exist.

Why is there no single federal rule requiring every Marketplace plan to cover obesity GLP-1s?

Prescription drugs are an essential health benefit category, but the federal drug standard is a category-and-class floor, not a requirement to cover Wegovy, Zepbound, Saxenda, or Foundayo by name. Anti-obesity medications are not categorically barred from essential health benefits. A state’s benchmark, the member’s contract, the formulary, and the utilization-management policy all matter.

Under 45 CFR 156.122(a)(1), a plan subject to essential health benefit requirements must cover at least the greater of one drug in every applicable United States Pharmacopeia category and class or the same number of drugs in each category and class as the state’s benchmark plan. That is a counting rule. It does not name Wegovy.

The federal list of benefits excluded from EHB under 45 CFR 156.115(d) does not include anti-obesity medication. So these drugs are not federally prohibited from EHB; they are simply not federally required by brand name for every state and plan.

The three layers that decide the answer

Source: Framework developed by The RX Index from 45 CFR 156.115, 45 CFR 156.122, CMS EHB benchmark materials, and the carrier documents cited on this page. Verified July 31, 2026.

A plan can satisfy Layer 1 without covering a specific obesity brand. A medical policy at Layer 3 cannot create a benefit that the member’s contract excludes at Layer 2. And a formulary listing alone cannot tell you which indication is covered.

The federal exception process still matters

The federal prescription-drug rule also requires a standard process for requesting a clinically appropriate drug that the plan does not otherwise cover, an expedited process for exigent circumstances, and independent external review after a denial. The standard and external deadlines are generally 72 hours; the expedited deadline is generally 24 hours. That does not mean every exception succeeds, and it does not erase contract language.

Twelve jurisdictions changed their EHB benchmark through plan year 2026

CMS’s current benchmark page lists approved changes for: Illinois for 2020; South Dakota for 2021; Michigan, New Mexico, and Oregon for 2022; Colorado for 2023; Vermont for 2024; North Dakota and Virginia for 2025; Alaska, the District of Columbia, and Washington for 2026. That is 12 unique jurisdictions through plan year 2026. CMS approved another Colorado change for 2027. Jurisdictions that did not use the update process continue with the benchmark in effect since plan year 2017.

North Dakota’s benchmark names the benefit

North Dakota’s approved benchmark materials add coverage for GLP-1 and GIP drugs as therapy for prevention of diabetes and treatment of insulin resistance, metabolic syndrome, or morbid obesity. The change took effect January 1, 2025 and reaches non-grandfathered individual and small-group plans.

The state also says prior authorization, reasonable medical management, and cost sharing can apply. That is why the correct North Dakota status is state benefit floor confirmed; drug and access details plan-specific, not “every person automatically gets every obesity drug.”

Does a formulary listing prove a Marketplace plan covers the drug for obesity?

No. A formulary shows how a drug appears in the pharmacy system. The contract establishes whether the member has the benefit. A prior-authorization policy explains how a request is evaluated when the policy applies. Excellus states the hierarchy directly: when the subscriber contract excludes a drug, its medical-policy criteria are not applied.

This is the evidence hierarchy used for every current row on this page:

The controlled evidence statuses used on this page:

A bare “Yes” or “No” has no date, no indication, and no document hierarchy. It is not enough.

Highmark shows why carrier-level answers fail

Highmark publishes two current anti-obesity benefit designs plus a transitional policy for established users. They are not interchangeable.

Source: Highmark J-1388-014, Highmark J-1389-010, and Highmark J-0184-043. Verified July 31, 2026.

The Enhanced policy’s current adult rule is not simply “BMI 40 plus two ordinary comorbidities.” It requires BMI of at least 40 and then one of two paths: a specified prediabetes/triglyceride/HDL cluster or at least two documented obesity-caused organ dysfunctions. It also separates benefit availability from medical-necessity approval and applies additional preferred-drug and step rules.

Does coverage differ for Wegovy, Zepbound, Saxenda, and newer 2026 products?

Yes. Coverage differs by drug, formulation, and indication. The historical 26-of-300 baseline tested only Wegovy, Zepbound, and Saxenda for obesity. It should never be silently expanded to newer products or alternate indications. A current tracker now needs separate rows for Foundayo, new Wegovy formulations, cardiovascular-risk use, MASH, and sleep-apnea use.

The historical numerator remains fixed to the three drugs the original producer reviewed. New approvals change the current landscape; they do not rewrite the old study.

Source: Current FDA approval notices and labeling for Foundayo, Wegovy injection and tablets, Wegovy 7.2 mg, Wegovy cardiovascular-risk indication, Wegovy for MASH, Zepbound for chronic weight management, and Zepbound for obstructive sleep apnea. Verified July 31, 2026.

KFF’s analysis of 2024 federally facilitated Marketplace formulary data found Ozempic on 82% of formularies and Wegovy on 1%. That comparison is two plan years old and excludes state-based-exchange data, but it is a clean historical illustration of the indication split.

What BMI, comorbidity, lifestyle-program, and renewal rules apply?

Having an anti-obesity benefit is not the same as qualifying for a specific drug. The public baseline says every positive carrier required three to nine months of documented reduced-calorie intake, exercise, and behavioral intervention immediately before the request, with inadequate weight loss. Current Highmark and Excellus policies show how sharply the details can diverge by product.

Source: Highmark J-1388-014, Highmark J-1389-010, and Excellus Pharmacy-03, last reviewed July 28, 2026. Verified July 31, 2026.

BMI classes

• Class 1 obesity: BMI 30 to less than 35
• Class 2 obesity: BMI 35 to less than 40
• Class 3 or severe obesity: BMI 40 or greater

BMI is a screening measure, not a diagnosis by itself. The insurance-policy use of a BMI threshold is a coverage rule, not a statement that BMI alone describes the person’s health.

Comorbidity rules

The phrase “plus two comorbidities” is not enough. A policy can require a named list, a metabolic cluster, or documented organ dysfunction caused by obesity. Highmark Enhanced uses the latter two paths in its current public policy. Excellus uses a listed comorbidity path at BMI 35–39.9.

Lifestyle-program documentation

A request can fail because the program was too short, did not include the required components, lacked verifiable attendance, or did not occur immediately before therapy. Excellus publishes minimum standards for its qualified comprehensive program. Highmark Standard and Enhanced use different minimum periods.

Step therapy and preferred products

A plan may prefer one obesity drug and require failure, intolerance, or contraindication before another. Highmark Enhanced identifies preferred-drug rules for current products. A statement that the carrier covers “the class” still does not tell a member which product can be approved first.

Renewal

Initial authorization and continued coverage are separate decisions. Policies can require a specified percentage of weight loss, maintenance of prior loss, continued participation in a lifestyle program, an approved maintenance dose, and recurring documentation. Approval once is not approval forever.

This section is educational, not clinical advice. Whether a medication is appropriate is a decision for a licensed prescriber. Whether a plan will cover it is governed by the member’s current contract and coverage process.

How was this ACA Marketplace GLP-1 dataset built and verified?

The dataset preserves the public LEVERAGE | AXIACI baseline as a dated source layer, then adds a separate current-evidence layer built from official issuer rosters, contracts or exclusion documents, formularies, and utilization-management policies. Every current conclusion is tied to an indication, evidence type, effective or review date, and verification date. Unresolved rows stay unresolved.

The steps are reproducible:

1. Define the plan year and the drug-and-indication scope.
2. Preserve the historical baseline exactly as published, including its counting unit and source date context.
3. Enumerate current medical QHP issuers and products from CMS or the state exchange; exclude dental-only issuers.
4. Preserve HIOS issuer IDs as text so leading zeros survive.
5. Separate consumer-facing product lines, legal issuers, HIOS issuer IDs, plan IDs, and formulary IDs.
6. Retrieve the exact Evidence of Coverage, Certificate of Coverage, rider, or benefit-exclusion document when public.
7. Search the contract layer for “weight loss,” “obesity,” “anti-obesity,” “excluded,” and every drug name.
8. Retrieve the plan-specific formulary and the applicable prior-authorization or medical-necessity policy.
9. Evaluate every drug and formulation separately.
10. Evaluate obesity, cardiovascular-risk reduction, MASH, obstructive sleep apnea, and diabetes separately.
11. Resolve conflicts using the evidence hierarchy on this page.
12. Record the document title, version or review date, effective date, retrieval date, and line of business.
13. Compare the current evidence with the historical baseline without overwriting either one.
14. Calculate derived statistics from visible source rows with formulas a reader can reproduce.
15. Mark anything that cannot be resolved as unresolved or plan-specific rather than guessing.

The preferred public row unit is: State + HIOS issuer + product line + contract/formulary combination.

The historical baseline and the original work on this page

The underlying national baseline was produced by LEVERAGE | AXIACI. The RX Index did not produce or license its nonpublic carrier rows. The RX Index’s original work is: the arithmetic on the nine public state rows; the 85.6% California concentration finding; the 22/24/21 BMI discrepancy reconciliation; the current Rhode Island and Vermont change analysis; the HIOS normalization of California’s 14 product lines to 11 issuers; the CMS denominator comparison; the indication-specific evidence vocabulary; the current policy architecture for Highmark and Excellus; and the dated source and change ledger.

Who produced the 26-of-300 baseline?

LEVERAGE | AXIACI produced the 26-of-300 Marketplace baseline through the Obesity Coverage Nexus, with funding support from the Robert Wood Johnson Foundation. The RX Index did not produce that national survey. It calculated new statistics from the public state table and built the current reconciliation layer.

Source: Attribution map compiled by The RX Index from the LEVERAGE | AXIACI public release and the primary documents listed on this page. Verified July 31, 2026.

Secondary coverage can be useful, but the clean source for the national baseline is the original producer. Becker’s Payer Issues correctly named LEVERAGE | AXIACI and the Robert Wood Johnson Foundation when it summarized the findings in December 2025. The original research should still be the citation for the 26-of-300 statistic.

What does this dataset show, and what can it not prove?

It shows what public source documents support on a stated verification date. It cannot promise approval, calculate an individual’s cost, establish unpublished carrier operations, or turn a carrier-family policy into proof about every product sold under that brand.

• There is no new national current count on this page. The historical national denominator was 300 carrier-state offerings. The current work rechecks the nine positive baseline states and does not establish the status of every offering in the other 41 states.
• Georgia’s current positive carrier is not named. The public baseline does not disclose it, and the current audit did not resolve it to a publishable standard.
• New York exclusivity is not established. Current Excellus and Highmark policy pathways were found, but the public baseline does not identify its three carriers and every 2026 New York issuer was not excluded.
• California’s current drug-level status is not established. The product and issuer roster is normalized, but the contract-level audit of all 14 product lines remains incomplete. Because California represents 85.6% of the baseline’s public access lives, this is the largest open current-data question.
• Rhode Island and Vermont are evidence conflicts, not proof of the exact date every member lost coverage. The baseline did not name the positive carrier. Current public documents do not support a positive ordinary obesity-benefit row, but the exact member EOC and effective history remain controlling.
• Plan availability varies by county. A carrier’s presence in a state does not mean every product is sold in every county.
• Carrier brands contain multiple legal issuers, products, benefit designs, and formularies. The California and Highmark sections show why brand-level rows are not enough.
• On-exchange and off-exchange documents can differ. A policy that applies to one line of business should not be assigned to another without an explicit line-of-business statement.
• A policy can change during the year. The contract, formulary, prior-authorization policy, and member notice can have different effective or review dates.
• Coverage is not affordability. A drug can be covered and still carry a deductible, coinsurance, quantity limit, or unaffordable out-of-pocket amount.
• CMS plan selections are not effectuated enrollment. The baseline’s market-segment column may also describe a broader population than CMS’s Marketplace plan-selection count.
• The historical three-drug scope is no longer a complete current-market scope. Foundayo and new Wegovy formulations and indications entered the 2026 evidence set after the baseline’s original design.

This page is educational. It is not medical, insurance, or legal advice. The controlling documents for an individual decision are the current documents issued for that exact plan, and medical decisions belong with a licensed prescriber.

How can someone verify a specific ACA Marketplace plan?

Start with the exact plan and contract, not the carrier’s brand name. Then read the benefit exclusion, formulary, and prior-authorization policy together, with the drug’s indication and every document date written down.

1. Record the state, county, carrier, full product name, metal level, and complete plan ID shown in the exchange account or plan documents.
2. Download the current Evidence of Coverage or Certificate of Coverage for that exact plan.
3. Search it for “weight loss,” “obesity,” “anti-obesity,” “excluded,” “prescription drug,” and each brand and molecule name.
4. If the contract appears to exclude the benefit, ask the carrier for the controlling section in writing and for the plan’s applicable exception and appeal instructions. Federal QHP drug rules include standard, expedited, and external exception processes, but the available route and likely result depend on the contract and the reason for noncoverage.
5. Open the plan-specific formulary and record the formulary ID, drug tier, prior-authorization flag, step-therapy flag, and quantity limit.
6. Open the current prior-authorization or medical-necessity policy and confirm the line of business includes on-exchange QHPs.
7. Identify the indication: obesity, cardiovascular-risk reduction, MASH, obstructive sleep apnea, diabetes, or another use. Do not substitute one for another.
8. Compare the effective or review date on the contract, formulary, policy, and member notice.
9. Ask the carrier to provide a written coverage determination tied to the exact plan, drug, formulation, indication, and prescriber request.
10. Save the documents and the written response. A later dispute is a document problem, and memory is not a document.

A prior-authorization approval does not guarantee payment. It establishes that the request met the approval process described by the plan; payment still depends on eligibility, active coverage, contract terms, network and pharmacy rules, coding or claim requirements, and cost sharing.

Frequently asked questions

How to cite this page

About this research. The RX Index Research publishes independent reference datasets on GLP-1 coverage, pricing, and access, assembled from dated public sources. This page carries no commercial relationships, product recommendations, sponsored placements, provider routing, or affiliate links.

Changelog